PuraPharm (HKG:1498) said it expects its H1 loss to widen year over year, according to a Hong Kong bourse filing Thursday.
Shares of the Chinese herbal medicine seller fell over 1% in recent afternoon trade.
The company is estimating a loss of about K$24 million for the six months ended June 30, widening from a loss of about HK$18.7 million a year prior.